

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2008; month=3; day=13; hr=11; min=48; sec=9; ms=975;]

=====

Application No: 10593071 Version No: 2.0

Input Set:

Output Set:

Started: 2008-02-29 14:58:53.518
Finished: 2008-02-29 14:58:54.041
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 523 ms
Total Warnings: 2
Total Errors: 0
No. of SeqIDs Defined: 15
Actual SeqID Count: 15

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)

SEQUENCE LISTING

<110> ROUGEOT, Catherine
HUAULME, Jean-Francois
UNGEHEUER, Marie-Noelle
WISNER, Anne
DUFOUR, Evelyne

<120> PEPTIDES DERIVED FROM HUMAN BPLP PROTEIN, POLYNUCLEOTIDES CODING
FOR SAID PEPTIDES AND ANTIBODIES DIRECTED AGAINST SAID PEPTIDES

<130> 296415US0PCT

<140> 10593071
<141> 2008-02-29

<150> PCT/IB05/00700
<151> 2005-03-18

<150> EPO 04290754.3
<151> 2004-03-19

<160> 15

<170> PatentIn version 3.3

<210> 1
<211> 947
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (81)..(686)

<400> 1
aattgagtat ctggcaagag taagattaag cagtaatttg ttccaaagaa gaatcttcta 60

ccaaggagca acttttaaaga atg aaa tta act ttc ttc ttg ggc ctg ttg gct 113
Met Lys Leu Thr Phe Phe Leu Gly Leu Leu Ala
1 5 10

ctt att tca tgt ttc aca ccc agt gag agt caa aga ttc tcc aga aga 161
Leu Ile Ser Cys Phe Thr Pro Ser Glu Ser Gln Arg Phe Ser Arg Arg
15 20 25

cca tat cta cct ggc cag ctg cca cca cct cca ctc tac agg cca aga 209
Pro Tyr Leu Pro Gly Gln Leu Pro Pro Pro Pro Leu Tyr Arg Pro Arg
30 35 40

tgg gtt cca cca agt ccc cca cct ccc tat gac tca aga ctt aat tca 257
Trp Val Pro Pro Ser Pro Pro Pro Pro Tyr Asp Ser Arg Leu Asn Ser
45 50 55

cca ctt tct ctt ccc ttt gtc cca ggg cga gtt cca cca tct tct ttc 305

[illegible]

Thr Pro Ser Glu Ser Gln Arg Phe Ser Arg Arg Pro Tyr Leu Pro Gly
20 25 30

Gln Leu Pro Pro Pro Pro Leu Tyr Arg Pro Arg Trp Val Pro Pro Ser
35 40 45

Pro Pro Pro Pro Tyr Asp Ser Arg Leu Asn Ser Pro Leu Ser Leu Pro
50 55 60

Phe Val Pro Gly Arg Val Pro Pro Ser Ser Phe Ser Arg Phe Ser Gln
65 70 75 80

Ala Val Ile Leu Ser Gln Leu Phe Pro Leu Glu Ser Ile Arg Gln Pro
85 90 95

Arg Leu Phe Pro Gly Tyr Pro Asn Leu His Phe Pro Leu Arg Pro Tyr
100 105 110

Tyr Val Gly Pro Ile Arg Ile Leu Lys Pro Pro Phe Pro Pro Ile Pro
115 120 125

Phe Phe Leu Ala Ile Tyr Leu Pro Ile Ser Asn Pro Glu Pro Gln Ile
130 135 140

Asn Ile Thr Thr Ala Asp Thr Thr Ile Thr Thr Asn Pro Pro Thr Thr
145 150 155 160

Ala Thr Ala Thr Thr Arg His Phe His Lys Thr His Asn Asp Asp Gln
165 170 175

Leu Leu Asn Ser Thr Tyr Leu Phe Asn Thr Arg Ala Cys His Leu His
180 185 190

Ile Ser Ser Asn Pro Arg Ser Ile Tyr
195 200

<210> 3
<211> 5
<212> PRT
<213> Homo sapiens

<400> 3

Gln Arg Phe Ser Arg
1 5

<210> 4
<211> 6
<212> PRT
<213> Homo sapiens

<400> 4

Tyr Gln Arg Phe Ser Arg
1 5

<210> 5
<211> 6
<212> PRT
<213> Homo sapiens

<400> 5

Cys Gln Arg Phe Ser Arg
1 5

<210> 6
<211> 6
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<222> (1)..(2)
<223> Xaa2 is Gln or Glp when Xaa1 is not present.

Xaa2 is Gln when Xaa1 is Tyr or Cys.

<400> 6

Xaa Xaa Arg Phe Ser Arg
1 5

<210> 7
<211> 5
<212> PRT
<213> Homo sapiens

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa1 is Glp.

<400> 7

Xaa Arg Phe Ser Arg

1 5

<210> 8
<211> 5
<212> PRT
<213> Rattus rattus

<400> 8

Gln His Asn Pro Arg
1 5

<210> 9
<211> 4
<212> PRT
<213> Rattus rattus

<400> 9

Gln His Asn Pro
1

<210> 10
<211> 5
<212> PRT
<213> Homo sapiens

<400> 10

Gln Arg Gly Pro Arg
1 5

<210> 11
<211> 7
<212> PRT
<213> Homo sapiens

<400> 11

Gln Arg Gly Pro Arg Gly Pro
1 5

<210> 12
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<220>

<221> MISC_FEATURE
 <222> (1)..(1)
 <223> Arg at position 1 is modified with (7-methoxycoumarin-4-yl)acetyl

 <220>
 <221> MISC_FEATURE
 <222> (10)..(10)
 <223> hydroxy substituted 2,4-dinitrophenyl amino acid

 <400> 12

 Arg Pro Pro Gly Phe Ser Ala Phe Lys Xaa
 1 5 10

 <210> 13
 <211> 3
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Synthetic Construct

 <220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> Ala at position 1 is modified with succinyl

 <220>
 <221> MISC_FEATURE
 <222> (3)..(3)
 <223> Phe at position 3 is modified with 7-amino-4-methyl coumarin

 <400> 13

 Ala Ala Phe
 1

 <210> 14
 <211> 11
 <212> PRT
 <213> Homo sapiens

 <400> 14

 Arg Phe Lys Phe Gln Gln Phe Phe Gly Leu Met
 1 5 10

 <210> 15
 <211> 5
 <212> PRT
 <213> Homo sapiens

 <400> 15

Tyr Gly Gly Phe Met
1 5